Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于深圳华大基因股份有限公司2020年度募集资金存放与实际使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by CITIC Securities regarding the 2020 annual fundraising funds deposit and actual usage of Shenzhen BGI Genomics Co., Ltd. It details the fundraising amount, usage, management, and compliance with regulatory requirements. The document includes detailed financial figures about the fundraising, usage, and management of funds, as well as audit opinions and compliance statements. It is a standalone audit-related report focusing on the use of raised capital, not a full annual report or earnings release. It is not a brief announcement or a presentation but a detailed verification report on fundraising usage. Therefore, it fits the definition of an Audit Report / Information (AR). The document length (9247 characters) and content confirm it is a full report, not just an announcement or certification letter. FY 2020
2021-04-25 Chinese
关于受让控股子公司少数股东股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of minority equity interests in the company's controlled subsidiaries, Shenzhen Medical Laboratory and Beijing Medical Laboratory, by the parent company Shenzhen BGI Genomics Co., Ltd. It includes information about the transaction parties, pricing, financial status of the subsidiaries, board and independent directors' approvals, and regulatory compliance. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a formal announcement of a capital transaction involving shareholding changes and related party transactions. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive disclosure of a financing-related transaction.
2021-04-25 Chinese
关于使用募集资金置换预先已投入募投项目自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in projects. It details the approval by the board and supervisory committee, references regulatory approvals, and includes auditor and sponsor opinions. The content focuses on the use and replacement of capital raised through a specific stock issuance, with no financial statements or quarterly/yearly financial results presented. The document is about a capital financing update related to the use of proceeds from a fundraising event. It is not an annual report, earnings release, or audit report, nor is it a simple announcement of a report publication. The document length is about 4749 characters, which is substantive and detailed, not a brief notice. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-04-25 Chinese
2020年度独立董事述职报告（徐爱民）
Board/Management Information Classification · 95% confidence The document is titled '2020 年度独立董事述职报告' which translates to '2020 Annual Independent Director's Work Report'. It details the independent director's attendance at board meetings, opinions on various company matters, committee work, investigations, investor protection efforts, and training during the 2020 fiscal year. The content focuses on the independent director's duties and activities rather than financial results or audit opinions. It is a detailed report on board/management activities and governance oversight by an independent director. This fits best under the category 'Board/Management Information (MANG)', which covers announcements or reports related to changes or activities of the company's board or senior management. The document is over 6,000 characters and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2021-04-25 Chinese
2020年度独立董事述职报告（蒋昌建）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the Year 2020" from Shenzhen BGI Genomics Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various board resolutions, committee work, investigations, investor protection efforts, and training during the year 2020. The content is a detailed narrative of the independent director's duties and performance over the fiscal year, which aligns with a management or board report rather than a financial statement or regulatory filing. It is not an annual report (10-K), audit report, earnings release, or any other financial report. It is also not a brief announcement or proxy solicitation. The document is a comprehensive report on the independent director's work and opinions, which fits best under Board/Management Information (MANG).
2021-04-25 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 30th meeting of the second board of directors of Shenzhen BGI Genomics Co., Ltd. It includes approvals of the 2020 annual report and its summary, the 2021 first quarter report, the 2020 board work report, the 2020 general manager work report, the 2020 financial final accounts and 2021 budget, the 2020 profit distribution plan, the reappointment of the 2021 audit firm, and other corporate governance matters. The document also references that the full 2020 annual report and 2021 first quarter report are published on the official disclosure website (cninfo.com.cn). The document is not the reports themselves but the board meeting resolutions approving these reports and other corporate decisions, which will be submitted to the shareholders' meeting for approval. This type of document is a Board/Management Information announcement, as it reports on board meeting decisions and management reports rather than being the full financial reports or earnings releases themselves.
2021-04-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.